Julia Zhao is an Analyst at Catalio Capital Management L.P.
Her technical expertise is in the field of pharmacogenomics and oncology where she profiles 3D organoids as novel drug screening platforms for targeted therapies in liver cancer.
Julia earned a B.A. in Neuroscience from Johns Hopkins University and is currently a Ph.D. Candidate in Biomedical Sciences at Icahn School of Medicine at Mount Sinai.